The Jackson Laboratory (JAX) Center for Precision Genetics (JCPG) will develop and disseminate new, precise animal models of incurable and genetically complex human diseases. The JCPG will leverage JAX's long-established expertise in mammalian genetics and disease modeling as well as the human clinical samples, data and collaborations fostered by The Jackson Laboratory for Genomic Medicine (JAX-GM), its newly established clinical genomics institute. The JCPG's international, multi-disciplinary team-including geneticists and genetics technology experts, molecular and computational biologists, clinical experts in specific disease areas and world leaders in the development of precision animal models of disease-will possess the collective ability to foresee disease modeling needs as they emerge and will serve investigators in a variety of disease areas on a regional, national and international basis. Initially six projects will address intractable or incurable diseases linkd by genetic complexity, molecular genetic data and/or humanization that represent diverse stages of preclinical development. The JCPG will:
Aim 1) Align investigator-initiated disease model research projects with institution-wide support to create efficient and goal-oriented preclinical pipelines;
Aim 2) Use heuristic program development in the pilot center research projects and cores to position JAX to be a fully functional center in five years, while nevertheles achieving tangible outcomes during the pilot period;
Aim 3) Embrace both realistic, cutting-edge technological platforms and ambitious high-risk, high-reward platforms as required to get the job done, i.e., advance paths to therapies for heretofore incurable diseases;
and Aim 4) Through JAX's many inter-institutional collaborations, identify and engage key clinical, foundation and corporate partners, who share our vision both for specific disease objectives, to help us navigate larger center goals. Ultimately, the JCPG will generate new disease modeling processes and pipelines, data resources, research results and models that will be swiftly shared through JAX's proven dissemination pipelines to accelerate translation to medical benefit.

Public Health Relevance

Despite recent advances in biomedical technology and methods, the translation of discoveries to useful clinical therapies remains inefficient and difficult. Organisms that model disease, a vital part of the translational process, need to be made more precise and more relevant to human disease mechanisms. The pilot JAX Center for Precision Genetics (JCPG) is a multi-component Center that will provide diverse research teams with the support and infrastructure necessary to develop, characterize and refine mouse models for incurable and genetically complex human diseases. The JCPG pipelines developed in this pilot project will be applicable and responsive to new disease areas, models and technological advances in forthcoming years.

National Institute of Health (NIH)
Office of The Director, National Institutes of Health (OD)
Specialized Center--Cooperative Agreements (U54)
Project #
Application #
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Mirochnitchenko, Oleg
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Jackson Laboratory
Bar Harbor
United States
Zip Code
Presa, Maximiliano; Racine, Jeremy J; Dwyer, Jennifer R et al. (2018) A Hypermorphic Nfkbid Allele Contributes to Impaired Thymic Deletion of Autoreactive Diabetogenic CD8+ T Cells in NOD Mice. J Immunol 201:1907-1917
Schloss, Jennifer; Ali, Riyasat; Racine, Jeremy J et al. (2018) HLA-B*39:06 Efficiently Mediates Type 1 Diabetes in a Mouse Model Incorporating Reduced Thymic Insulin Expression. J Immunol 200:3353-3363
Racine, Jeremy J; Stewart, Isabel; Ratiu, Jeremy et al. (2018) Improved Murine MHC-Deficient HLA Transgenic NOD Mouse Models for Type 1 Diabetes Therapy Development. Diabetes 67:923-935
Chiang, Wei-Chieh; Chan, Priscilla; Wissinger, Bernd et al. (2017) Achromatopsia mutations target sequential steps of ATF6 activation. Proc Natl Acad Sci U S A 114:400-405
Tian, Cong; Gagnon, Leona H; Longo-Guess, Chantal et al. (2017) Hearing loss without overt metabolic acidosis in ATP6V1B1 deficient MRL mice, a new genetic model for non-syndromic deafness with enlarged vestibular aqueducts. Hum Mol Genet 26:3722-3735
Korstanje, Ron; Ryan, Jennifer L; Savage, Holly S et al. (2017) Continuous Glucose Monitoring in Female NOD Mice Reveals Daily Rhythms and a Negative Correlation With Body Temperature. Endocrinology 158:2707-2712
Snyder, Elizabeth M; McCarty, Christopher; Mehalow, Adrienne et al. (2017) APOBEC1 complementation factor (A1CF) is dispensable for C-to-U RNA editing in vivo. RNA 23:457-465
Wang, Qiming; Racine, Jeremy J; Ratiu, Jeremy J et al. (2017) Transient BAFF Blockade Inhibits Type 1 Diabetes Development in Nonobese Diabetic Mice by Enriching Immunoregulatory B Lymphocytes Sensitive to Deletion by Anti-CD20 Cotherapy. J Immunol 199:3757-3770
Rodvold, Jeffrey J; Chiu, Kevin T; Hiramatsu, Nobuhiko et al. (2017) Intercellular transmission of the unfolded protein response promotes survival and drug resistance in cancer cells. Sci Signal 10:
Liu, Edison T; Bolcun-Filas, Ewelina; Grass, David S et al. (2017) Of mice and CRISPR: The post-CRISPR future of the mouse as a model system for the human condition. EMBO Rep 18:187-193

Showing the most recent 10 out of 13 publications